Medium Spiny Neurons (MSNs)

Medium Spiny Neurons (MSNs)

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Medium Spiny Neurons (MSNs)</th>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:1001474](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_1001474)</td>
</tr>
<tr>
<td class="label">Source</td>
<td>Neurotransmitter</td>
</tr>
<tr>
<td class="label">Cerebral cortex (all layers)</td>
<td>Glutamate</td>
</tr>
<tr>
<td class="label">Thalamus (intralaminar nuclei)</td>
<td>Glutamate</td>
</tr>
<tr>
<td class="label">Substantia nigra pars compacta</td>
<td>Dopamine</td>
</tr>
<tr>
<td class="label">Raphe nuclei</td>
<td>Serotonin</td>
</tr>
<tr>
<td class="label">Basal forebrain</td>
<td>Acetylcholine</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Normal Function</td>
</tr>
<tr>
<td class="label">Dopamine</td>
<td>Motor control</td>
</tr>
<tr>
<td class="label">BDNF</td>
<td>MSN survival</td>
</tr>
<tr>
<td class="label">mTOR</td>
<td>Protein synthesis</td>
</tr>
<tr>
<td class="label">Autophagy</td>
<td>Protein clearance</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Gene silencing</td>
<td>HTT mRNA</td>
</tr>
<tr>
<td class="label">BDNF enhancement</td>
<td>TrkB agonists</td>
</tr>
<tr>
<td class="

Medium Spiny Neurons (MSNs)

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Medium Spiny Neurons (MSNs)</th>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:1001474](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_1001474)</td>
</tr>
<tr>
<td class="label">Source</td>
<td>Neurotransmitter</td>
</tr>
<tr>
<td class="label">Cerebral cortex (all layers)</td>
<td>Glutamate</td>
</tr>
<tr>
<td class="label">Thalamus (intralaminar nuclei)</td>
<td>Glutamate</td>
</tr>
<tr>
<td class="label">Substantia nigra pars compacta</td>
<td>Dopamine</td>
</tr>
<tr>
<td class="label">Raphe nuclei</td>
<td>Serotonin</td>
</tr>
<tr>
<td class="label">Basal forebrain</td>
<td>Acetylcholine</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Normal Function</td>
</tr>
<tr>
<td class="label">Dopamine</td>
<td>Motor control</td>
</tr>
<tr>
<td class="label">BDNF</td>
<td>MSN survival</td>
</tr>
<tr>
<td class="label">mTOR</td>
<td>Protein synthesis</td>
</tr>
<tr>
<td class="label">Autophagy</td>
<td>Protein clearance</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Gene silencing</td>
<td>HTT mRNA</td>
</tr>
<tr>
<td class="label">BDNF enhancement</td>
<td>TrkB agonists</td>
</tr>
<tr>
<td class="label">Autophagy enhancement</td>
<td>mTOR inhibition</td>
</tr>
<tr>
<td class="label">CRISPR editing</td>
<td>CAG repeat</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Features</td>
</tr>
<tr>
<td class="label">R6/2 transgenic</td>
<td>Aggressive HD phenotype</td>
</tr>
<tr>
<td class="label">YAC128</td>
<td>Slower progression</td>
</tr>
<tr>
<td class="label">Q175 knock-in</td>
<td>More physiological</td>
</tr>
<tr>
<td class="label">QA lesion</td>
<td>Excitotoxic MSN loss</td>
</tr>
<tr>
<td class="label">Species</td>
<td>Conservation Level</td>
</tr>
<tr>
<td class="label">Mouse</td>
<td>High</td>
</tr>
<tr>
<td class="label">Human</td>
<td>Reference</td>
</tr>
<tr>
<td class="label">Macaque</td>
<td>High</td>
</tr>
<tr>
<td class="label">Zebra finch</td>
<td>Moderate</td>
</tr>
</table>

Overview

Medium spiny neurons (MSNs) are the principal neurons of the striatum (caudate nucleus and putamen), comprising approximately 95% of striatal neurons. Named for their medium-sized cell bodies (~12-20 μm) and spiny dendrites, they are GABAergic projection neurons that form the primary output pathway of the basal ganglia. Degeneration of MSNs is the hallmark of Huntington's disease, making them critical to understanding movement disorders and basal ganglia circuit dysfunction.

Multi-Taxonomy Classification

Taxonomy Database Cross-References

Morphology & Electrophysiology

• Morphology: medium spiny neuron (source: Cell Ontology)
• Morphology can be inferred from Cell Ontology classification

Classification & Lineage

• Parent Classification: GABAergic
• Full Lineage: Neuron > GABAergic > Striatal
• Brain Regions: Caudate nucleus, Putamen, Nucleus accumbens

External Database Links

• [Cell Ontology (CL:1001474)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_1001474)
• [OBO Foundry (CL:1001474)](http://purl.obolibrary.org/obo/CL_1001474)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [Human Cell Atlas](https://www.humancellatlas.org/)

Neuroanatomy

Striatal Organization

The striatum is the largest component of the basal ganglia:

• Dorsal striatum: Caudate nucleus (cognitive) and putamen (motor)
• Ventral striatum: Nucleus accumbens core and shell (reward/motivation)
• Striosomes (patches): ~10-15% of striatum, high μ-opioid receptor, limbic inputs
• Matrix: ~85-90%, sensorimotor and associative inputs

Cellular Morphology

Soma: 12-20 μm diameter, relatively small compared to cortical pyramidal cells

Dendrites:

• 3-5 primary dendrites radiating from soma
• Covered in dense spines (10,000-15,000 per neuron)
• Spine density correlates with excitatory synaptic input
• Spine head volume reflects synaptic strength

• Extensive local axon collaterals (intrastriatal)
• Long projection axon to globus pallidus/substantia nigra
• Initial segment at ~50-100 μm from soma

Input Projections

Molecular Biology

Dopamine Receptor Expression

The fundamental division of MSNs is based on dopamine receptor expression:

D1-Expressing MSNs (Direct Pathway)

• DRD1 receptor: Gs/Golf-coupled, excitatory effect of dopamine
• Express substance P, dynorphin
• Project to GPi and SNr (substantia nigra pars reticulata)
• Express transcription factor Isl1[@lobo2010]

• DRD2 receptor: Gi/Go-coupled, inhibitory effect of dopamine
• Express enkephalin (PENK)
• Project to GPe (globus pallidus externa)
• Express transcription factor Foxp1[@vernay2018]

GABA Synthesis and Release

Glutamic acid decarboxylase (GAD67/GAD1, GAD65/GAD2):

• Converts glutamate to GABA
• GAD67 is cytosolic, involved in metabolism
• GAD65 is membrane-associated, synaptic vesicle-linked

• Loads GABA into synaptic vesicles
• Also transports glycine

Transcription Factors

Key transcription factors in MSN specification:

• CTIP2 (BCL11B): MSN identity, required for striatal development[@arlotta2008]
• Isl1: Direct pathway specification
• Foxp1/2: Indirect pathway specification
• FOXP1 mutations: Cause HD-like syndrome

DARPP-32 (PPP1R1B)

Dopamine- and cAMP-regulated phosphoprotein, 32 kDa:

• Key signaling integrator in MSNs
• Phosphorylation at Thr34: PKA-dependent, inhibits PP1 → enhanced signaling
• Phosphorylation at Thr75: Cdk5-dependent, inhibits PKA → reduced signaling
• Integrates dopamine, glutamate, serotonin signals[@svenningsson2004]

Electrophysiology

Resting Properties

• Resting membrane potential: ~-80 mV
• Hyperpolarized due to inward-rectifier K+ channels (Kir2)
• Very negative threshold: requires strong depolarization
• Input resistance: 100-300 MΩ (high)

Up and Down States

MSNs exhibit bistable membrane potential states:

Down State:

• Hyperpolarized (~-80 mV)
• Minimal synaptic input
• No action potential firing

• Depolarized (~-50 mV)
• Active cortical/thalamic input
• Action potentials can be generated
• Transition driven by coordinated excitatory input[@wilson2007]

Firing Patterns

• Low spontaneous firing rate (<1 Hz)
• During up states: 5-20 Hz
• Action potentials followed by afterhyperpolarization
• Paired-pulse facilitation at cortical inputs

Basal Ganglia Circuits

Direct Pathway (D1-MSNs)

Cortex → Striatum (D1-MSN) → GPi/SNr → Thalamus → Cortex
+--------------------+
DISINHIBITS

• D1-MSN activation inhibits GPi/SNr
• Reduced GPi/SNr inhibition of thalamus
• Result: Movement facilitation

Indirect Pathway (D2-MSNs)

Cortex → Striatum (D2-MSN) → GPe → STN → GPi/SNr → Thalamus → Cortex
+---------------+------+------+----------+
NET INHIBITION

• D2-MSN activation inhibits GPe
• Disinhibition of STN (excitatory to GPi/SNr)
• Increased GPi/SNr inhibition of thalamus
• Result: Movement suppression

Balanced Output

Normal motor control requires balanced direct/indirect pathway activity:

• Dopamine facilitates direct pathway (D1 excitation)
• Dopamine inhibits indirect pathway (D2 inhibition)
• Net effect: Promotes desired movements, suppresses unwanted movements

Huntington's Disease Pathophysiology

MSN Vulnerability Pattern

Huntington's disease (HD) shows characteristic selective vulnerability:

Early stages:

• Preferential D2-MSN (indirect pathway) loss
• Enkephalin-expressing neurons degenerate first
• Results in chorea via reduced indirect pathway suppression

• D1-MSN (direct pathway) loss
• Progressive bradykinesia develops
• Both pathways eventually affected

Mutant Huntingtin Mechanisms

Huntingtin protein (HTT):

• Normal: 10-35 CAG repeats (polyglutamine tract)
• HD: >36 CAG repeats → expanded polyQ
• Mutant HTT forms aggregates (inclusion bodies)

• Transcriptional dysregulation (SP1, CREB dysfunction)
• Impaired BDNF trafficking from cortex
• Mitochondrial dysfunction
• Synaptic dysfunction (excitotoxicity)
• Proteasome impairment

Excitotoxicity Hypothesis

• Excessive glutamate from cortical inputs
• NMDA receptor overactivation
• Calcium overload
• MSNs have high NMDA receptor expression
• QUIN model replicates MSN loss in animals

Altered Signaling

Other Neurodegenerative Diseases

Parkinson's Disease

• MSNs receive dopaminergic input from SNpc
• Dopamine loss leads to:
• D2-MSN disinhibition (indirect pathway overactive)
• D1-MSN reduced excitation (direct pathway underactive)
• Net effect: Excessive movement suppression (bradykinesia)

Multiple System Atrophy (MSA)

• Striatal degeneration in MSA-P type
• Combined SNpc and striatal pathology
• Poor levodopa response due to postsynaptic loss

Wilson's Disease

• Copper accumulation in basal ganglia
• MSN degeneration
• Movement disorder with psychiatric features

Therapeutic Targets

HD Symptomatic Treatment

Chorea:

• Tetrabenazine (VMAT2 inhibitor): Depletes dopamine
• Deutetrabenazine: Longer half-life
• Antipsychotics: D2 blockade

• Physical therapy
• Amantadine (may help bradykinesia)

Disease-Modifying Approaches

Experimental Approaches

Cell replacement:

• Fetal striatal tissue transplants
• iPSC-derived MSNs
• Challenges: integration, connectivity, HD environment

• GPi DBS for chorea
• Limited evidence for disease modification

Research Methods

Animal Models

In Vitro Models

• Primary striatal cultures
• iPSC-derived MSNs from HD patients
• Organoid models with striatal components

Key References

Brain Atlas Resources

• [Allen Cell Type Atlas - Medium Spiny Neurons](https://celltypes.brain-map.org/)
• [Allen Mouse Brain Atlas - Medium Spiny Neurons](https://mouse.brain-map.org/)
• [BrainSpan - Medium Spiny Neurons Developmental Transcriptome](https://brainspan.org/)
• [Allen Human Brain Atlas - Medium Spiny Neurons Expression](https://human.brain-map.org/microarray)
• [Neurons](/cell-types/neurons) Major brain cell type
• Glia — Suppor- [Alzheimer's Disease](/diseases/alzheimers-disease)Alzhe- [Parkinson's Disease](/diseases/parkinsons-disease)d neurodegenerative disease
• [Parkinson's Disease](/diseases/parkinsons-disease) Related neurodegenerative disease

External Links

• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature

Cross-species Conservation

BICAN/ABC Atlas Taxonomy

This cell type belongs to the [GABAergic](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas) class, specifically the Striatal medium spiny neuron subclass in the BICAN (Brain Initiative Cell Atlas Network) taxonomy.

The BICAN taxonomy provides a standardized classification of cell types across species, enabling cross-species comparisons of neuronal and glial cell populations.

Cell Ontology Mapping

Cell Ontology terms for this cell type:

• [medium spiny neuron](https://obofoundry.org/ontology/cl/cl/1001474.html) (CL:1001474)

Cross-species Conservation Overview

This cell type shows varying degrees of conservation across model organisms:

Research Applications

• Evolutionary studies: Understanding conserved mechanisms across species
• Disease modeling: Cross-species validation of disease mechanisms
• Drug testing: Translating findings from mouse models to human therapeutics

References